ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ASM Avino Silver and Gold Mines Ltd

1.07
0.04 (3.88%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Avino Silver and Gold Mines Ltd AMEX:ASM AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.04 3.88% 1.07 1.07 1.02 1.05 1,199,415 23:36:30

De-List from NASDAQ Europe

26/08/2003 8:00am

UK Regulatory


RNS Number:9993O
Antisoma PLC
26 August 2003


Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market
            Shares to remain listed on the London Stock Exchange


26 August 2003, London, UK: Antisoma  (LSE: ASM- Nasdaq Europe: ASOM), the
UK-based biopharmaceutical company, today announces that it has received
approval for a voluntary de-listing from the Nasdaq Europe Market. The
de-listing of Antisoma shares will be effective from the close of business on
Wednesday 10 September 2003. The decision to de-list follows the announcement by
Nasdaq Europe of its intention to close by the end of November 2003.

Following the de-listing, all Antisoma shares will continue to be traded on the
London Stock Exchange, where the majority of trading takes place at present.
Existing shareholders will not have to take any action to transfer their
shareholdings. Importantly, they will not incur any additional costs as a result
of the de-listing.

Antisoma will continue to provide its shareholders with press releases and
related company information on www.antisoma.com.



Enquiries:


Antisoma plc
Raymond Spencer, Chief Financial Officer                Tel: +44 (0)20 8799 8200

Financial Dynamics

Jonathan Birt                                           Tel: +44 (0)7884 238952





About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the pre-clinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma signed a ground-breaking collaboration agreement with Roche to
develop and commercialise products from Antisoma's pipeline.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCPUUQARUPWGRP

1 Year Avino Silver and Gold Mi... Chart

1 Year Avino Silver and Gold Mi... Chart

1 Month Avino Silver and Gold Mi... Chart

1 Month Avino Silver and Gold Mi... Chart

Your Recent History

Delayed Upgrade Clock